Compare Gogoro Inc (GGR) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gogoro Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Gogoro Inc trades at $2.5 (market cap $52.19M), while Vertex Pharmaceuticals Incorporated trades at $526.45 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2572.3× Gogoro Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Gogoro Inc nearer its low. Which is the better fit depends on your goals.
| GGR | VRTX | |
|---|---|---|
Market Cap | $52.19M | $134.25B |
Sector | Technology | Health |
52-Week High | $7.50 | $529.65 |
52-Week Low | $2.55 | $376.62 |
Enterprise Value | $354.63M | $128.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GGR trades at $2.63, up 1.94% today, with a bearish technical signal from moving averages but oversold RSI readings. The company reported a net loss of $79.97 million on $281.48 million revenue in 2025, with negative margins and cash flow, though 2026 projections show improvement. Analyst consensus is entirely hold, reflecting caution amid ongoing losses.
Outlook remains challenging with persistent losses and negative cash flow, but low P/S and P/B ratios may attract value investors if operational improvements materialize. Key risks include execution on profitability, competitive pressures, and reliance on future growth initiatives to achieve sustained positive earnings.
Vertex Pharmaceuticals (VRTX) trades at $526.33, up 0.46% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with 2025 revenue of $12.0B and net income of $3.95B, though recent Q2 2026 earnings slightly missed estimates. Analyst sentiment remains positive with an 83.9% buy rating and a $534.25 consensus price target, while news highlights raised 2026 sales guidance driven by cystic fibrosis drug strength and newer product launches.
The outlook for VRTX is favorable given robust revenue growth, high profitability margins, and raised full-year guidance. Key opportunities include diversification beyond cystic fibrosis with newer products, but risks involve earnings volatility, competitive pressures, and execution on pipeline developments. The stock's valuation at a P/E of 30.85 requires sustained growth to justify further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gogoro Inc
Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.
Read more on GGR →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
